WO2025149009 - PRMT5 INHIBITOR, AND COMPOSITION AND PHARMACEUTICAL USE THEREOF
National phase entry is expected:
Publication Number
WO/2025/149009
Publication Date
17.07.2025
International Application No.
PCT/CN2025/071645
International Filing Date
10.01.2025
Title **
[English]
PRMT5 INHIBITOR, AND COMPOSITION AND PHARMACEUTICAL USE THEREOF
[French]
INHIBITEUR DE PRMT5, COMPOSITION ET UTILISATION PHARMACEUTIQUE ASSOCIÉES
[Chinese]
一种PRMT5抑制剂及其组合物和药物用途
Applicants **
ALICORN PHARMACEUTICAL CO., LTD
Inventors
LU, Pingbo
ZHU, Hui
LI, Zhouyang
ZHU, Di
FANG, Hao
NIU, Qingjiang
ZHU, Chao
LU, Xin
CENG, Yue
Priority Data
202410052831.7
13.01.2024
CN
202410427310.5
10.04.2024
CN
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| Number of Office Actions | * |
| * | |
International Searching Authority |
CNIPA
* |
| Recordal of a Change of the Applicant's Name/Address |
Change of Applicant's Name and Address
* |
| Type of Assignment |
The Standard Agent's Assignment
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Patent Delivery |
Send the Letters Patent by Courier
* |
| Translation |
|
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing, Examination, Granting | 2075 | |
| EPO | Filing, Examination, Granting | 14248 | |
| Japan | Filing, Examination, Granting | 2277 | |
| South Korea | Filing, Examination, Granting | 2431 | |
| USA | Filing, Examination, Granting | 5340 |
Total:
26,371
Contact Us
Abstract[English]
The present invention relates to a heterocyclic compound for inhibiting PRMT5 activity, and a stereoisomer thereof, or a pharmaceutically acceptable salt thereof. The heterocyclic compound for inhibiting PRMT5 activity has a structure as represented by formula (I). Further provided in the present invention are a composition containing the compound and the use thereof as a PRMT5 inhibitor.[French]
La présente invention concerne un composé hétérocyclique pour inhiber l'activité de PRMT5, et un stéréoisomère de celui-ci, ou un sel pharmaceutiquement acceptable de celui-ci. Le composé hétérocyclique pour inhiber l'activité de PRMT5 a une structure telle que représentée par la formule (I). La présente invention concerne en outre une composition contenant le composé et son utilisation en tant qu'inhibiteur de PRMT5.[Chinese]
本发明涉及抑制PRMT5活性的杂环化合物及其立体异构体、或其药学上可接受的盐，该抑制PRMT5活性的杂环化合物具有如式(I)所示结构。本发明还进一步提供了包含所述化合物的组合物及其作为PRMT5抑制剂的用途。